A systematic review of angiotensin receptor blockers in preventing stroke

source extracted confidence: high 2026-04-09
#angiotensin-ii #angiotensin-receptor-antagonists #angiotensin-converting-enzyme-inhibitors #calcium-channel-blockers #cardiovascular-diseases

A systematic review of angiotensin receptor blockers in preventing stroke

Lu et al., 2009 | Stroke | Meta Analysis

Citation

Lu Guo-Cai, Cheng Jin-Wei, ... Su Ding-Feng. A systematic review of angiotensin receptor blockers in preventing stroke. Stroke. 2009-Dec;40(12):3876-8. doi:10.1161/STROKEAHA.109.559989

Abstract

BACKGROUND AND PURPOSE: Angiotensin receptor blockers are widely used in patients at high risk of cardiocerebrovascular events. The aim of this meta-analysis was to investigate the effects of angiotensin receptor blockers on the risk of stroke. METHODS: Electronic searches of MEDLINE, EMBASE, and the Cochrane central register of controlled trials were performed. A total of 20 randomized clinical trials with 108 286 patients reporting stroke were available for this clinical outcome analysis. RESULTS: Angiotensin receptor blockers were associated with a significant reduction in the risk of stroke than placebo with an OR of 0.91 (0.84 to 0.98). Angiotensin receptor blockers were associated with no significant reduction in the risk of stroke compared with angiotensin-converting enzyme inhibitors (OR, 0.93; 0.84 to 1.03) and calcium antagonists (OR, 1.16; 0.91 to 1.48). CONCLUSIONS: Evidence of the benefit of angiotensin receptor blockers on the risk of stroke is provided when compared with placebo. There was no evidence of the benefit when comparing angiotensin receptor blockers with angiotensin-converting enzyme inhibitors and with calcium antagonists.

Key Findings

Angiotensin receptor blockers were associated with a significant reduction in the risk of stroke than placebo with an OR of 0.91 (0.84 to 0.98). Angiotensin receptor blockers were associated with no significant reduction in the risk of stroke compared with angiotensin-converting enzyme inhibitors (OR, 0.93; 0.84 to 1.03) and calcium antagonists (OR, 1.16; 0.91 to 1.48).

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 286
Age Range See abstract
Condition See abstract

MeSH Terms

  • Angiotensin II
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Cardiovascular Diseases
  • Humans
  • Hypertension
  • Randomized Controlled Trials as Topic
  • Receptors, Angiotensin
  • Risk Factors
  • Stroke
  • Treatment Outcome

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Letter, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: calcium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09